This Small-Cap Stock Announced a Deal With Eli Lilly. Then Its Shares Doubled
Eli Lilly is partnering with Ginkgo Bioworks on drug discovery.
Eli Lilly, a major healthcare company, recently entered into a partnership with Ginkgo Bioworks, a biotech stock. This collaboration aims to leverage Ginkgo's vast data points and AI capabilities to accelerate drug discovery efforts. Ginkgo, which has a market cap of approximately $1 billion, saw its shares double in value following the announcement of the deal on September 15th.
Although investors may be wondering if it is too late to buy Ginkgo shares or if there is still potential for further gains, the excitement surrounding this partnership has clearly had a significant impact on the stock's performance.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
